7 results

  • brenzavvy

    (Bexagliflozin)
    TheracosBio, LLC
    BRENZAVVY is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes mellitus.

  • farxiga

    (DAPAGLIFLOZIN)
    AstraZeneca Pharmaceuticals LP
    FARXIGA (dapagliflozin) is indicated to reduce risks of kidney disease progression, cardiovascular death, and heart failure in adults with chronic kidney disease or heart failure. Additionally, it improves glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes as an adjunct to diet and exercise.

  • glyxambi

    (empagliflozin and linagliptin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    GLYXAMBI, a combination of empagliflozin and linagliptin, is indicated to improve glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Empagliflozin also reduces cardiovascular death risk in patients with type 2 diabetes and existing cardiovascular disease. It is not suitable for type 1 diabetes or certain conditions.

  • inpefa

    (sotagliflozin)
    Lexicon Pharmaceuticals, Inc.
    INPEFA is indicated for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

  • jardiance

    (Empagliflozin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    JARDIANCE is indicated for reducing the risk of cardiovascular death and hospitalization in adults with heart failure, chronic kidney disease, and type 2 diabetes with established cardiovascular disease. It also aids glycemic control as an adjunct to diet and exercise in patients aged 10 and older with type 2 diabetes.

  • synjardy

    (empagliflozin and metformin hydrochloride)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    SYNJARDY and SYNJARDY XR are indicated as adjuncts to diet and exercise to improve glycemic control in adults and pediatric patients (≥10 years) with type 2 diabetes mellitus. Empagliflozin also reduces the risk of cardiovascular death and heart failure hospitalization in adults with established cardiovascular disease.

  • trijardy xr

    (empagliflozin, linagliptin, metformin hydrochloride)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    TRIJARDY XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin within the combination helps reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Not for type 1 diabetes.